Overview

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects

Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, 3-Cohort, parallel, single-dose, study to evaluate the PK, safety, and tolerability of ATI-2173 50 mg administered orally in Japanese, Chinese, and Non-Asian healthy subjects incorporating a food effect analysis in Non-Asian healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Antios Therapeutics, Inc